DV 1179

Drug Profile

DV 1179

Alternative Names: DV1079; DV1179

Latest Information Update: 21 Dec 2015

Price : $50

At a glance

  • Originator Dynavax Technologies
  • Class Oligonucleotides
  • Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders; Inflammation
  • Discontinued Systemic lupus erythematosus

Most Recent Events

  • 21 Dec 2015 Phase-I development for Inflammation and Autoimmune disorders is ongoing in USA
  • 28 Nov 2014 Dynavax Technologies regains full rights to DV 1179
  • 07 Aug 2014 Adverse events data from a phase Ib/IIa trial in Systemic lupus erythematosus released by Dynavax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top